

Express Mail Label
No. EV625768081US

PATENTS
AAB-1 Cont.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Applicants : Anette Israelsson et al.
Application No. : 10/762,034 Confirmation No. : 3924
Filed : January 20, 2004
For : HYDROPHILIC URINARY CATHETER
HAVING A WATER-CONTAINING SACHET
TC Art Unit : 3761
Examiner : Michele M. Kidwell

New York, New York 10020
May 19, 2005


Mail Stop AMENDMENT
Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT

Sir:

The Director is hereby authorized to charge \$260.00, in payment of the \$130.00 fee set forth in 37 C.F.R. § 1.20(d) for each of the accompanying Terminal Disclaimers Under 37 C.F.R. § 1.321(b,c) in the above-identified patent application, and any additional fee due in connection with the accompanying Terminal Disclaimers, or the accompanying Reply to Office Action, to Deposit Account No. 06-1075 (Order No. 000834-0002).

Respectfully submitted,



Jeffrey H. Ingerman
Reg. No. 31,069
Attorney for Applicants
FISH & NEAVE IP GROUP
ROPES & GRAY LLP
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1105
Tel.: (212) 596-9000



Express Mail Label
No. EV625768081US

PATENTS
AAB-1 Cont.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Applicants : Anette Israelsson et al.
Application No. : 10/762,034 Confirmation No. : 3924
Filed : January 20, 2004
For : HYDROPHILIC URINARY CATHETER
HAVING A WATER-CONTAINING SACHET
TC Art Unit : 3761
Examiner : Michele M. Kidwell

Mail Stop AMENDMENT
Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

TERMINAL DISCLAIMER
UNDER 37 C.F.R. § 1.321(b,c)

Sir:

AstraZeneca AB, a corporation of Sweden, having its principal office and place of business at 151 85 Södertälje, Sweden, represents that it is the assignee of record of the entire, right, title and interest, by virtue of an assignment recorded at Reel 9333, Frames 383-86, from the inventors to Astra AB, and a change of name from Astra AB to AstraZeneca AB recorded at Reel 14409, Frames 393-99, of the following issued United States patent and pending United States patent application:

1. U.S. Patent No. 6,409,717 for "HYDROPHILIC URINARY CATHETER HAVING A WATER-CONTAINING SACHET," issued June 25, 2002 on Application No. 08/809,481, filed March 21, 1997.

05/24/2005 NNGUYEN1 00000084 061075 10762034

01 FC:1814 130.00 DA

2. Application No. 10/762,034, filed January 20, 2004 as a continuation of copending Application No. 10/160,390, filed May 31, 2002 as a continuation of Application No. 08/809,481, filed March 21, 1997. The assignment of the '481 application is effective for the '390 application as a continuation of a continuation.

The undersigned, on behalf of AstraZeneca AB, hereby disclaims the terminal portion of the term of any patent to be issued on the present application, Application No. 10/762,034, which would extend beyond the expiration date (currently January 22, 2017*), of the full statutory term of U.S. Patent 6,409,717.

The undersigned, on behalf of AstraZeneca AB, agrees that any patent to be issued on the present Application No. 10/762,034 shall be enforceable only for and during such period as the legal title to such patent shall be the same as the legal title to said Patent No. 6,409,717, this agreement to run with any patent to be issued on Application No. 10/762,034 and to be binding upon the grantee of such patent and its successors and assigns.

The undersigned, on behalf of AstraZeneca AB, does not disclaim any terminal part of the term of any patent, to be issued on the above-identified Application No. 10/762,034, that would extend to the expiration date (currently January 22, 2017*), of the full statutory term of U.S. Patent 6,409,717, in the event that U.S. Patent 6,409,717: (a) expires for failure to pay a maintenance fee, (b) is held unenforceable, (c) is found invalid, (d) is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a,b), (e) has all claims cancelled

* It is applicants' and assignee's intention that if any change in the patent statutes, or the awarding of patent term adjustment, changes the expiration date of grandparent Patent 6,409,717, then the date beyond which the term of any patent to issue on this application is disclaimed shall change along with the expiration date of the grandparent patent.


by a reexamination certificate, or (f) is otherwise terminated prior to expiration of its statutory term, except for the separation of legal title stated above.

The undersigned hereby states and certifies that:

1. He is an attorney of record in the above-identified patent application and is authorized to act on behalf of assignee corporation in connection with said application; and

2. The relevant evidentiary documents have been reviewed and, to the best of the undersigned's and assignee's knowledge and belief, title to the above-identified Application No. 10/762,034 is in assignee.

AstraZeneca AB

By: 
Jeffrey H. Ingerman
Reg. No. 31,069
Attorney for Applicants
and Assignee
FISH & NEAVE IP GROUP
ROPES & GRAY LLP
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1105
Tel.: (212) 596-9000

5/19/05
Date

New York, New York